藍帆醫療(002382.SZ):北京信聿持股比例減少5%
格隆匯3月11日丨藍帆醫療(002382.SZ)公佈,2019年8月16日-2021年3月10日公司持股5%以上股東北京信聿投資中心(有限合夥)(原名為北京中信投資中心(有限合夥),於2020年12月28日將名稱變更為北京信聿投資中心(有限合夥),以下簡稱“北京信聿”)通過集中競價、大宗交易方式累計減持公司股份3585.76萬股,北京信聿持有公司股份由1.91億股減少至1.55億股。
截至2021年3月10日,因公司可轉換公司債券持有人轉股,使得公司總股本由9.64億股增加至10.47億股,公司持股5%以上股東北京信聿所持有的公司股份比例被動稀釋。
綜合上述原因,北京信聿主動減持3585.76萬股,減持後持有公司股份1.55億股;同時,持股比例因總股本增加被動稀釋,股份主動減持和被動稀釋後佔公司現總股本比例為14.80%,持股比例下降達到5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.